Business context and reporting period
Filing identity: The supplied filing is Diffusion Pharmaceuticals Inc. (formerly RestorGenex Corporation), not Cervomed Inc. It is a Form 10-K for the fiscal year ended December 31, 2015. Its audited financial statements cover legacy RestorGenex; they do not include Diffusion Pharmaceuticals LLC’s historical 2015 results.
On January 8, 2016, the company completed its merger with Diffusion LLC, which is treated as the accounting acquirer in a reverse acquisition. The combined company is focused on TSC, an investigational drug intended to improve oxygenation in tumors and enhance standard cancer treatments. Former Diffusion LLC owners received approximately 84.1% of the combined company on a fully diluted basis. The filing states 101,578,512 common shares were outstanding as of March 21, 2016.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $23.83 million | $14.61 million |
| Operating loss | $23.83 million | $14.61 million |
| Net loss | $23.82 million | $14.35 million |
| Net loss per share | $1.28 | $1.00 |
| Cash used in operating activities | $9.60 million | $9.03 million |
| Cash and cash equivalents at year-end | $12.01 million | $21.88 million |
| Working capital at year-end | $10.97 million | $21.83 million |
Gross margin and operating margin are not meaningful because the company had no revenue. Cash used in investing activities was $0.28 million in 2015; financing activities provided no cash, versus $30.71 million in 2014, principally from a private placement. The 2015 net loss included an $11.07 million non-cash goodwill impairment and $0.97 million in former-employee severance expense. Total assets were $19.92 million, total liabilities $3.48 million, and stockholders’ equity $16.44 million at December 31, 2015.
Legacy RestorGenex reported no outstanding debt on its year-end balance sheet. Following the merger, the company assumed $1.125 million of convertible notes, bearing 1% annual interest, plus approximately $38,000 of accrued interest at closing. These notes mature from 2016 to 2019 and are convertible into common shares.
Material changes versus the prior period
- Operating expenses rose 63%, primarily due to the $11.07 million goodwill impairment; R&D increased to $3.85 million from $2.86 million and general and administrative costs increased to $7.91 million from $4.76 million.
- Net loss widened to $23.82 million from $14.35 million. The 2014 comparison included $6.67 million of intangible-asset impairment, $2.31 million of losses on note settlements, and a $2.82 million tax benefit, none of which had a comparable 2015 amount.
- Cash declined by $9.88 million during 2015, compared with a $21.63 million increase in 2014, when the company raised net proceeds of approximately $31.85 million through an equity financing.
- The merger materially changed the company’s business, ownership, leadership, headquarters, name and trading symbol. The 2015 financial statements do not reflect Diffusion LLC’s pre-merger results.
Outlook, commentary and risks
- Funding and going concern: Management estimated year-end cash would fund planned operations into the third quarter of 2016, but said funding might be needed sooner. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern without additional capital. The company reported paying $3.26 million in merger-related severance in January 2016. Equity financing could dilute shareholders; unavailable financing could delay, reduce or stop development.
- TSC in glioblastoma: The 59-patient Phase 1/2 study completed in 2015 reported two-year survival of 36.3% versus 26.5% in a historical control, and one-year survival of 71% versus 61%. These comparisons were against historical data, not a concurrent control group. The company reported no serious adverse events attributed to TSC in the study. FDA discussions agreed that one randomized, open-label Phase 3 study of 400 newly diagnosed patients, if successful, could support an approval application. Trial initiation depended on financing and completion of manufacturing and animal-toxicology requirements; management said it intended to begin within 12 months.
- Other development: The company was discussing FDA trial design for pancreatic cancer and anticipated enrollment in a Phase 2/3 study in the first half of 2017, subject to funding. A brain-metastases trial was also planned, pending further FDA discussions. The company expected R&D spending to increase as it pursued clinical trials.
- Principal risks: TSC remains investigational; later-stage trials may fail or be delayed, regulatory approval is uncertain, and additional capital is essential. The company also relies on contract manufacturers and other third parties, has no commercial-scale manufacturing capability or sales force, faces competition, and may encounter intellectual-property, reimbursement and commercialization challenges.
- Contingencies and unusual items: A former RestorGenex CEO’s employment-related claims were in arbitration, with outcome and potential loss not estimable and a potentially material effect possible. A Diffusion member’s note-conversion suit was dismissed on March 14, 2016, but the plaintiff could amend the complaint. Legacy RestorGenex stockholders received contingent value rights tied to possible RES-440 transaction proceeds over five years, capped at $50 million in aggregate; payment is not assured.
Important facts for investors to verify
- Confirm the company and filing identity: the filing is for Diffusion Pharmaceuticals Inc., formerly RestorGenex, rather than Cervomed Inc.
- Review post-merger cash, cash burn, financing activity and runway, including the effect of the January 2016 severance payments.
- Check whether the agreed Phase 3 glioblastoma trial’s funding, manufacturing and toxicology prerequisites were met, and assess the trial results against its prespecified endpoints and control arm.
- Track the status and terms of the assumed convertible notes, potential share dilution, and the merger’s fully diluted capitalization.
- Monitor the legal proceedings, the RES-440 contingent value rights, and any changes in going-concern disclosures.